CONNECT WITH US
eCommerce

eCommerce

EXCLUSIVE: Skin Pharm Expands Nationwide Footprint With Northeast Clinic

WWD logo

Published on

Add as a preferred source on Google
EXCLUSIVE: Skin Pharm Expands Nationwide Footprint With Northeast Clinic

Opening Thursday, the new spot will be located at 149 Newbury Street in Boston.

Skin Pharm, the Nashville-based aesthetic skin care practice and product line founded by board-certified nurse practitioner Maegan Griffin, is entering the Northeast market with a new clinic.

Opening Thursday, the new spot will be situated at 149 Newbury Street in Boston. This marks the company’s 18th location nationwide, with existing clinics in Georgia, Virginia, Texas, North Carolina, South Carolina, Illinois, Tennessee and Florida.

“One of the biggest reasons we’re opening in Boston is we see a strong social media following from people in that market,” said Brad Griffin, president of Skin Pharm. “We also see a strong pull from Massachusetts and the Northeast in general when it comes to our online skin care sales.”

Skin Pharm launched its product line in 2018, a year after the first clinic was established. The assortment now comprises cleansers, serums, toners, masks and moisturizers, all of which target a range of skin concerns, from acne to aging and fine lines. Its bestsellers include the Crystal Clear Clarifying Toner Pads, $50, and the High Beam Brightening Lotion, $90.

The full lineup is available inside all Skin Pharm locations and offered alongside treatments such as platelet-rich plasma, microneedling, facial balancing and a signature Gold Infusion — a stamping method designed to stimulate collagen production, tighten pores and hydrate the skin.

“We have an intentional menu of services,” Maegan Griffin said. “We’re blending signature wrinkle relaxers and neuromodulators, but we’re also doing regenerative treatments.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.